Medicus Pharma Statistics
Total Valuation
Medicus Pharma has a market cap or net worth of $10.03 million. The enterprise value is $16.50 million.
| Market Cap | 10.03M |
| Enterprise Value | 16.50M |
Important Dates
The next estimated earnings date is Friday, November 13, 2026, before market open.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Medicus Pharma has 63.18 million shares outstanding. The number of shares has increased by 173.46% in one year.
| Current Share Class | 63.18M |
| Shares Outstanding | 63.18M |
| Shares Change (YoY) | +173.46% |
| Shares Change (QoQ) | +86.37% |
| Owned by Insiders (%) | 16.73% |
| Owned by Institutions (%) | 10.01% |
| Float | 52.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.57
| Current Ratio | 1.57 |
| Quick Ratio | 1.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -44.04 |
Financial Efficiency
Return on equity (ROE) is -7,446.11% and return on invested capital (ROIC) is -153.66%.
| Return on Equity (ROE) | -7,446.11% |
| Return on Assets (ROA) | -110.67% |
| Return on Invested Capital (ROIC) | -153.66% |
| Return on Capital Employed (ROCE) | -212.45% |
| Weighted Average Cost of Capital (WACC) | 2.47% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.33% in the last 52 weeks. The beta is -0.48, so Medicus Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.48 |
| 52-Week Price Change | -94.33% |
| 50-Day Moving Average | 0.26 |
| 200-Day Moving Average | 0.66 |
| Relative Strength Index (RSI) | 30.67 |
| Average Volume (20 Days) | 10,514,135 |
Short Selling Information
The latest short interest is 3.36 million, so 5.31% of the outstanding shares have been sold short.
| Short Interest | 3.36M |
| Short Previous Month | 2.79M |
| Short % of Shares Out | 5.31% |
| Short % of Float | 6.38% |
| Short Ratio (days to cover) | 2.04 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -34.58M |
| Pretax Income | -56.73M |
| Net Income | -56.66M |
| EBITDA | n/a |
| EBIT | -34.58M |
| Earnings Per Share (EPS) | -$1.66 |
Balance Sheet
The company has $15.17 million in cash and $21.64 million in debt, with a net cash position of -$6.46 million or -$0.10 per share.
| Cash & Cash Equivalents | 15.17M |
| Total Debt | 21.64M |
| Net Cash | -6.46M |
| Net Cash Per Share | -$0.10 |
| Equity (Book Value) | -1.72M |
| Book Value Per Share | -0.03 |
| Working Capital | 6.14M |
Cash Flow
| Operating Cash Flow | -29.32M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | 16.44M |
| Free Cash Flow | -29.32M |
| FCF Per Share | -$0.46 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Medicus Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -173.46% |
| Shareholder Yield | -173.46% |
| Earnings Yield | -564.76% |
| FCF Yield | -292.23% |
Analyst Forecast
The average price target for Medicus Pharma is $4.50, which is 2,733.75% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.50 |
| Price Target Difference | 2,733.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 25, 2024. It was a reverse split with a ratio of 1:2.
| Last Split Date | Oct 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |